
1. Mar Drugs. 2020 May 28;18(6). pii: E284. doi: 10.3390/md18060284.

Novel Fredericamycin Variant Overproduced by a Streptomycin-resistant
Streptomyces albus subsp. chlorinus Strain.

Rodríguez Estévez M(1), Myronovskyi M(1), Rosenkränzer B(1), Paululat T(2),
Petzke L(3), Ristau J(3), Luzhetskyy A(1)(4).

Author information: 
(1)Pharmazeutische Biotechnologie, Universität des Saarlandes, 66123 Saarbrücken,
Germany.
(2)Organische Chemie II, Universität Siegen, 57068 Siegen, Germany.
(3)BASF SE, 67056 Ludwigshafen, Germany.
(4)Helmholtz-Institut für Pharmazeutische Forschung Saarland, 66123 Saarbrücken, 
Germany.

Streptomycetes are an important source of natural products potentially applicable
in the pharmaceutical industry. Many of these drugs are secondary metabolites
whose biosynthetic genes are very often poorly expressed under laboratory
cultivation conditions. In many cases, antibiotic-resistant mutants exhibit
increased production of natural drugs, which facilitates the identification and
isolation of new substances. In this study, we report the induction of a type II 
polyketide synthase gene cluster in the marine strain Streptomyces albus subsp.
chlorinus through the selection of streptomycin-resistant mutants, resulting in
overproduction of the novel compound fredericamycin C2 (1). Fredericamycin C2 (1)
is structurally related to the potent antitumor drug lead fredericamycin A.

DOI: 10.3390/md18060284 
PMCID: PMC7345809
PMID: 32481766  [Indexed for MEDLINE]

Conflict of interest statement: The authors declare no conflict of interest.

